CAR-T firm Autolus bags $80 million in Series C financing
Autolus, a London-based clinical-stage biotechnology company specialized in the development and commercialization of next-generation engineered T cell therapies, has announced that it has raised US$80 million (£59 million) in Series C financing.
Autolus, a London-based clinical-stage biotechnology company specialized in the development and commercialization of next-generation engineered T cell therapies, has announced that it has raised US$80 million (£59 million) in Series C financing.
The Series C follows the £70 million Series A and B financings taking the total amount of financing raised by Autolus to date to around £129 million. The company will use the funds to establish clinical proof of concept to initiate three clinical trials for four haematological cancer indications- multiple myeloma, diffuse large B cell lymphoma, paediatric acute lymphoblastic leukaemia and T cell lymphoma.
The fundraising campaign was supported by new investors, Cormorant Asset Management and Nextech Invest along with the founding investors Syncona Ltd, Woodford Investment Management and Arix Bioscience.
By utilizing its established cell programming and manufacturing technology platforms, Autolus also plans to advance its pre-clinical pipeline products for solid tumor indications. It will also use the funds to set up the infrastructure required to bring CAR-T cell therapy to market.
Unlike first-generation CAR-Ts, Autolus’ products are designed to target two separate cancer-associated antigens, which it hopes will enhance their potency. For instance, their 3rd generation CAR-T candidate for multiple myeloma is designed to simultaneously target two antigens found on multiple myeloma cells- B-cell maturation antigen and transmembrane activator and calcium modulator and cyclophilin ligand interactor.
ارسال به دوستان